News Breaks |
|
|
| December 24, 2012 |
| 08:20 EDT |  | RPTP | Raptor Pharma weakness may provide buying opportunity, says Oppenheimer
After Raptor announced that the FDA had postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, Oppneheimer views the news as a short-term negative for the company but doesn't think it has any implication on the FDA's ultimate decision about Procysbi. The firm maintains an Outperform rating on Raptor. |
|
|
News For RPTP From The Last 14 Days Check below for free stories on RPTP the last two weeks. |
|
|
| June 19, 2013 |
| 07:08 EDT |  | RPTP | Raptor Pharmaceuticals Procysbi now commercially available in U.S.
Raptor Pharmaceutical announced that Procysbi delayed-release capsules are now available in the U.S. for shipment to cystinosis patients. FDA approved Procysbi on April 30 for the management of nephropathic cystinosis in adults and children ages 6 years and older. Initial prescription claims have been approved by multiple payor categories and Procysbi is being shipped to patients. |
|
| June 13, 2013 |
| 12:03 EDT |  | RPTP | Raptor Pharmaceuticals management to meet with Leerink
 Subscribe for More Information |
|
|
|
|
|
